Abstract
Coronary artery disease is the leading cause of death in the UK with a high clinical, social and economic burden. The management of acute coronary syndromes is rapidly evolving and clinicians are constantly challenged with incorporating new clinical pathways and guidelines into their practices. It is important for clinicians to have a sound working knowledge of acute coronary syndromes, and be updated on the emerging evidence to guide therapy and improve outcomes in these patients.
MeSH terms
-
Angioplasty, Balloon, Coronary* / methods
-
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
-
Anticoagulants / therapeutic use
-
Antithrombins / therapeutic use
-
Clopidogrel
-
Fondaparinux
-
Heparin, Low-Molecular-Weight / therapeutic use
-
Hirudins
-
Humans
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
-
Myocardial Infarction / drug therapy
-
Myocardial Infarction / mortality
-
Myocardial Infarction / prevention & control
-
Myocardial Infarction / therapy*
-
Peptide Fragments / therapeutic use
-
Platelet Aggregation Inhibitors / therapeutic use
-
Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors
-
Polysaccharides / therapeutic use
-
Recombinant Proteins / therapeutic use
-
Thrombolytic Therapy*
-
Ticlopidine / analogs & derivatives
-
Ticlopidine / therapeutic use
Substances
-
Angiotensin-Converting Enzyme Inhibitors
-
Anticoagulants
-
Antithrombins
-
Heparin, Low-Molecular-Weight
-
Hirudins
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors
-
Peptide Fragments
-
Platelet Aggregation Inhibitors
-
Platelet Glycoprotein GPIIb-IIIa Complex
-
Polysaccharides
-
Recombinant Proteins
-
Clopidogrel
-
Fondaparinux
-
Ticlopidine
-
bivalirudin